Hefei Lifeon Pharmaceuticals (003020.SZ): Application for registration and approval of marketing authorization for Telmisartan Potassium Tablets (40mg and 80mg) has been accepted.

Hefei Lifeon Pharmaceutical (003020.SZ) announced that they have recently received a "Notice of Acceptance" for the registration and listing application of the drug telmisartan potassium tablets (40mg and 80mg) issued by the National Medical Products Administration. It is reported that telmisartan potassium is a precursor drug of angiotensin II receptor blockers, which can be quickly converted into the active ingredient azilsartan after oral absorption. The product applying for the market approval this time is the tablet form of telmisartan potassium, which is used to treat primary hypertension in adults. The original research company is Takeda Pharmaceutical Company Ltd. of Japan. As of the date of this announcement, in addition to imported products, there is one domestic company holding the drug approval number for this product.